medigraphic.com
Instituto Nacional de Salud Pública

2010, Number 6

<< Back Next >>

salud publica mex 2010; 52 (6)

Short-term risk of cervical intraepithelial neoplasia grades 2 and 3 for women with normal cytology and human papillomavirus infection

Hernández-Suárez G, Ortiz N, González M, Muñoz N

Language: English
References: 33
Page: 486-492
PDF size: 132.42 Kb.


ABSTRACT

Objective. To assess the risk of cervical intraepithelial neoplasia grades 2, 3 or higher (CIN 2/3+) for women with normal cytology and concurrent high-risk human papillomavirus infection (HR-HPV). Material and Methods. We examined 2 200 women every 6 months for an average of 9 years. Cervical smears and samples for HPV DNA were obtained at each visit. Absolute risk of subsequent CIN2/CIN3+ was estimated using the Kaplan-Meier method. Results. The absolute risk of CIN2/CIN3+ among HR-HPVpositive women with normal Pap smear results was 1.06% (95%CI, 0.57–2.20), 5 times higher the risk among all women with normal Pap smears (0.20%; 95%CI, 0.12–0.32) but 7 times lower than that for women with HR-HPV infection and LSIL (7.24%; 95%CI, 3.78–15.2). Conclusion. Short-term absolute risk of CIN2/3+ after a normal Pap smear with concurrent HR-HPV infection is low (~1%), suggesting that the HR-HPV test has limited utility in short-term clinical decision-making for women with normal cytology.


REFERENCES

  1. Castellsague X, Munoz N. Chapter 3: Cofactors in human papillomavirus carcinogenesis--role of parity, oral contraceptives, and tobacco smoking. J Natl Cancer Inst Monogr 2003(31):20-8.

  2. Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-9.

  3. Arbyn M, Paraskevaidis E, Martin-Hirsch P, Prendiville W, Dillner J. Clinical utility of HPV-DNA detection: triage of minor cervical lesions, follow-up of women treated for high-grade CIN: an update of pooled evidence. Gynecol Oncol 2005;99(3 Suppl 1):S7-11.

  4. Cuzick J, Clavel C, Petry KU, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer 2006;119(5):1095-101.

  5. Wright TC, Jr., Schiffman M, Solomon D, et al. Interim Guidance for the Use of Human Papillomavirus DNA Testing as an Adjunct to Cervical Cytology for Screening. Obstet Gynecol 2004;103(2):304-9.

  6. Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362(9399):1871-6.

  7. R. A. Smith, V. Cokkinides, and H. J. Eyre. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin, January 1, 2003; 53(1): 27 - 43 (Accessed Sept 1, 2006, at http://caonline. amcancersoc.org/cgi/content/full/52/6/342.)

  8. Kitchener HC, Almonte M, Gilham C, et al. ARTISTIC: a randomised trial of human papillomavirus (HPV) testing in primary cervical screening. Health Technol Assess 2009;13(51):1-150, iii-iv.

  9. Bulkmans NW, Berkhof J, Rozendaal L, et al. Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial. Lancet 2007;370(9601):1764-72.

  10. Naucler P, Ryd W, Tornberg S, et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007;357(16):1589-97.

  11. Leinonen M, Nieminen P, Kotaniemi-Talonen L, et al. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting. J Natl Cancer Inst 2009;101(23):1612-23.

  12. Lazcano-Ponce E, Lorincz AT, Salmeron J, et al. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program. Cancer Causes Control, 2010.

  13. Castle PE, Wacholder S, Sherman ME, et al. Absolute risk of a subsequent abnormal pap among oncogenic human papillomavirus DNApositive, cytologically negative women. Cancer 2002;95(10):2145-51.

  14. Sherman ME, Lorincz AT, Scott DR, et al. Baseline cytology, human papillomavirus testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003;95(1):46-52.

  15. Kjaer S, Hogdall E, Frederiksen K, et al. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 2006;66(21):10630-6.

  16. Carozzi F, Ronco G, Confortini M, et al. Prediction of high-grade cervical intraepithelial neoplasia in cytologically normal women by human papillomavirus testing. Br J Cancer 2000;83(11):1462-7.

  17. Liaw KL, Glass AG, Manos MM, et al. Detection of human papillomavirus DNA in cytologically normal women and subsequent cervical squamous intraepithelial lesions. J Natl Cancer Inst 1999;91(11):954-60.

  18. Sackett DL, Deeks JJ, Altman DG. Down with odds ratios! Evidence- Based Med 1996; 1: 164-166.

  19. Molano M, Posso H, Weiderpass E, et al. Prevalence and determinants of HPV infection among Colombian women with normal cytology. Br J Cancer 2002;87(3):324-33.

  20. Jacobs MV, Snijders PJ, van den Brule AJ, Helmerhorst TJ, Meijer CJ, Walboomers JM. A general primer GP5+/GP6(+)-mediated PCR-enzyme immunoassay method for rapid detection of 14 high-risk and 6 low-risk human papillomavirus genotypes in cervical scrapings. J Clin Microbiol 1997;35(3):791-5.

  21. Munoz N, Bosch FX, de Sanjose S, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003;348(6):518-27.

  22. Luff RD. The Bethesda System for reporting cervical/vaginal cytologic diagnoses: report of the 1991 Bethesda workshop. The Bethesda System Editorial Committee. Hum Pathol 1992;23(7):719-21.

  23. Gage JC, Hanson VW, Abbey K, et al. Number of cervical biopsies and sensitivity of colposcopy. Obstet Gynecol 2006;108(2):264-72.

  24. Schlecht NF, Platt RW, Negassa A, et al. Modeling the time dependence of the association between human papillomavirus infection and cervical cancer precursor lesions. Am J Epidemiol 2003;158(9):878-86.

  25. Hedeker D, Siddiqui O, Hu FB. Random-effects regression analysis of correlated grouped-time survival data. Statistical Methods in Medical Research 2000;9(2):161-79.

  26. Munoz N, Mendez F, Posso H, et al. Incidence, duration, and determinants of cervical human papillomavirus infection in a cohort of Colombian women with normal cytological results. J Infect Dis 2004;190(12):2077-87.

  27. Munoz N, Hernandez-Suarez G, Mendez F, et al. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 2009;100(7):1184-90.

  28. Castle PE, Fetterman B, Poitras N, Lorey T, Shaber R, Kinney W. Fiveyear experience of human papillomavirus DNA and Papanicolaou test cotesting. Obstet Gynecol 2009;113(3):595-600.

  29. Ronco G, Giorgi-Rossi P, Carozzi F, et al. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test. J Natl Cancer Inst 2008;100(7):492-501.

  30. Castle PE, Rodriguez AC, Burk RD, et al. Short term persistence of human papillomavirus and risk of cervical precancer and cancer: population based cohort study. Bmj 2009;339:b2569.

  31. Castle PE, Solomon D, Schiffman M, Wheeler CM. Human papillomavirus type 16 infections and 2-year absolute risk of cervical precancer in women with equivocal or mild cytologic abnormalities. J Natl Cancer Inst 2005;97(14):1066-71.

  32. Cervical carcinoma and reproductive factors: collaborative reanalysis of individual data on 16,563 women with cervical carcinoma and 33,542 women without cervical carcinoma from 25 epidemiological studies. Int J Cancer 2006;119(5):1108-24.

  33. Bozzetti M, Nonnenmacher B, Mielzinska II, et al. Comparison between hybrid capture II and polymerase chain reaction results among women at low risk for cervical cancer. Ann Epidemiol 2000;10(7):466




2020     |     www.medigraphic.com